Updates are available Correction dated 2022-04-28
Click to view Correction: https://doi.org/10.1007/s00259-022-05810-z
-
Authors
Vaz, Sofia C. http://orcid.org/0000-0003-4229-9349
Adam, Judit A. http://orcid.org/0000-0001-8899-8087
Delgado Bolton, Roberto C. http://orcid.org/0000-0002-8071-6513
Vera, Pierre
van Elmpt, Wouter
Herrmann, Ken
Hicks, Rodney J. http://orcid.org/0000-0002-0758-0824
Lievens, Yolande http://orcid.org/0000-0002-9157-3730
Santos, Andrea http://orcid.org/0000-0001-9931-8446
Schöder, Heiko http://orcid.org/0000-0002-5170-4185
Dubray, Bernard http://orcid.org/0000-0001-9891-2777
Visvikis, Dimitris http://orcid.org/0000-0003-0831-3637
Troost, Esther G. C. http://orcid.org/0000-0001-9550-9050
de Geus-Oei, Lioe-Fee http://orcid.org/0000-0003-1817-2743
-
Funding
Funding for this research was provided by:
Universität Duisburg-Essen
- License Information
-
More Information
Article History
Received: 5 October 2021
Accepted: 15 November 2021
First Online: 13 January 2022
Change Date: 28 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-022-05810-z
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work.Rodney J. Hicks is on the Scientific Advisory Board of Telix Pharmaceuticals with any honoraria donated to his institution, he is a stock holder in this company, and he is also an honorary Trustee of the International Cancer Imaging Society and honorary Board Member of Neuroendocrine Cancer Australia.All the remaining authors declare no conflict of interest.
: This guideline summarizes the views of the EANM Oncology and Theranostics Committee, the SNMMI and ESTRO. It reflects recommendations for which the EANM/SNMMI/ESTRO cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and radiation oncology and do not substitute for national and international legal or regulatory provisions.
